Predictors of corticosteroid‐dependent and corticosteroid‐refractory inflammatory bowel disease: analysis of a Chinese cohort study

Background  Patients with inflammatory bowel disease (IBD) who are corticosteroid‐dependent or ‐refractory are at higher risk of developing disease‐ and treatment‐related complications.

[1]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[2]  T. Piche Impact de la chirurgie gynécologique sur le développement du syndrome de l’intestin irritable et des douleurs abdominales , 2008 .

[3]  F. Chan,et al.  Changes in Crohn's disease phenotype over time in the Chinese population: Validation of the Montreal classification system , 2008, Inflammatory bowel diseases.

[4]  A. Zinsmeister,et al.  Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.

[5]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[6]  S. Hutfless,et al.  Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. , 2007, Gastroenterology.

[7]  Gerald Gartlehner,et al.  Serious adverse events with infliximab: analysis of spontaneously reported adverse events. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[9]  G. Leandro,et al.  Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission , 2007, The American Journal of Gastroenterology.

[10]  A. Zinsmeister,et al.  A population‐based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis , 2006, Inflammatory bowel diseases.

[11]  H. Drummond,et al.  The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohort , 2006, Alimentary pharmacology & therapeutics.

[12]  S. Dorn Predictors of Crohn's disease. , 2006, Gastroenterology.

[13]  J. Mary,et al.  Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. , 2006, Gastroenterology.

[14]  W. Tremaine,et al.  American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[15]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[16]  P. Rutgeerts,et al.  Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down Therapy , 2005 .

[17]  J. Sung,et al.  The Epidemiology and Phenotype of Crohn’s Disease in the Chinese Population , 2004, Inflammatory bowel diseases.

[18]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[19]  P. Hellström,et al.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County , 2004, Gut.

[20]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[21]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee , 2004, American Journal of Gastroenterology.

[22]  G. Rogler,et al.  Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease , 2002, American Journal of Gastroenterology.

[23]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[24]  P. Keeling,et al.  High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. , 2000, Gastroenterology.

[25]  J. Belaiche,et al.  Clinical pattern of corticosteroid dependent Crohn's disease , 1998, European journal of gastroenterology & hepatology.

[26]  J. Berlin,et al.  Risk factors for early postoperative recurrence of Crohn's disease. , 1998, Gastroenterology.

[27]  P. Munkholm,et al.  Frequency of glucocorticoid resistance and dependency in Crohn's disease. , 1994, Gut.

[28]  P. Munkholm,et al.  Colorectal cancer risk and mortality in patients with ulcerative colitis. , 1992, Gastroenterology.

[29]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[30]  G. Hellers,et al.  Prognosis and mortality of ulcerative colitis in Stockholm County, 1955-1979. , 1987, Scandinavian journal of gastroenterology.

[31]  K. Ewe,et al.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.

[32]  R. Fraser,et al.  CAPTOPRIL, ANGIOTENSIN II, AND SODIUM IN BLOOD-PRESSURE REGULATION , 1979, The Lancet.

[33]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[34]  J. Lennard-jones,et al.  CLINICAL OUTCOME OF THE FIRST TEN YEARS OF ULCERATIVE COLITIS AND PROCTITIS , 1978, The Lancet.

[35]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.

[36]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .